Compare ACRS & SWBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | SWBI |
|---|---|---|
| Founded | 2012 | 1852 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ordnance And Accessories |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 608.9M | 651.8M |
| IPO Year | 2015 | 2000 |
| Metric | ACRS | SWBI |
|---|---|---|
| Price | $5.71 | $15.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $10.20 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 2.0M | 1.1M |
| Earning Date | 05-07-2026 | 06-17-2026 |
| Dividend Yield | N/A | ★ 3.37% |
| EPS Growth | ★ 69.01 | 36.67 |
| EPS | N/A | ★ 0.41 |
| Revenue | $1,683,000.00 | ★ $523,845,000.00 |
| Revenue This Year | N/A | $7.61 |
| Revenue Next Year | $4.24 | $3.72 |
| P/E Ratio | ★ N/A | $37.49 |
| Revenue Growth | N/A | ★ 10.36 |
| 52 Week Low | $1.46 | $7.73 |
| 52 Week High | $5.76 | $17.56 |
| Indicator | ACRS | SWBI |
|---|---|---|
| Relative Strength Index (RSI) | 71.95 | 53.00 |
| Support Level | $4.13 | $13.83 |
| Resistance Level | N/A | $17.56 |
| Average True Range (ATR) | 0.31 | 0.84 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 92.26 | 30.90 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.